79P Indirect treatment comparisons of durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab + olaparib vs pembrolizumab + CP followed by pembrolizumab and vs dostarlimab + CP followed by dostarlimab as first-line treatment for mismatch repair-proficient endometrial cancer

Key Points

• This research aims to compare the efficacy and safety of different first-line treatment combinations for mismatch repair proficient endometrial cancer.
• Conducted indirect treatment comparisons (ITCs) among three phase III trials: RUBY-1, NRG-GY018, and DUO-E.
• Compared CP+dostarlimab vs CP+pembrolizumab, and CP+durvalumab+olaparib vs CP alone for efficacy in pMMR patients.
• Focused on progression-free survival (PFS) as a key outcome measure.
• CP+dostarlimab showed lower efficacy rates compared to CP+durvalumab+olaparib in pMMR patients, indicating significant improvements with the latter.
• PFS benefits were notably higher for the CP+durvalumab+olaparib combination compared to CP alone, emphasizing enhanced treatment effectiveness.
• ITC results support the use of combination therapy in improving outcomes for pMMR interim sub-populations.